Globus Medical (GMED)
(Delayed Data from NYSE)
$74.88 USD
+1.34 (1.82%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $74.90 +0.02 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$74.88 USD
+1.34 (1.82%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $74.90 +0.02 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum D VGM
Zacks News
Compared to Estimates, Globus Medical (GMED) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Globus Medical (GMED) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 1.69% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Higher Visits to Soften Cost Blow for Teladoc (TDOC) Q4 Earnings
by Zacks Equity Research
Teladoc's (TDOC) fourth-quarter results are likely to reflect growth in BetterHelp's profit levels.
Can Low Patient Days Affect Community Health (CYH) Q4 Earnings?
by Zacks Equity Research
Community Health's (CYH) fourth-quarter results are likely to reflect lower adjusted admissions, declining beds in services and occupancy rate.
Will Nevro (NVRO) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical (GMED) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Globus Medical (GMED), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
The Zacks Analyst Blog Highlights Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics
by Zacks Equity Research
Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics are included in this Analyst Blog.
Globus Medical (GMED) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medtech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.
Can Tenet's (THC) Q4 Earnings Beat on Rising Patient Admissions?
by Zacks Equity Research
Tenet's (THC) fourth-quarter results are likely to reflect higher Ambulatory Care operating revenues and supply costs.
Encompass Health (EHC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Encompass Health's (EHC) fourth-quarter results are likely to reflect pricing increases and growing volumes.
Will High Medical Costs Affect Centene's (CNC) Q4 Earnings?
by Zacks Equity Research
Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and overall memberships.
Cigna (CI) to Report Q4 Earnings: Can Rising Expenses Hurt?
by Zacks Equity Research
Cigna's (CI) fourth-quarter results are likely to reflect growth in Evernorth revenues and customer base.
Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Can Higher Costs Affect HCA Healthcare's (HCA) Q4 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter results are likely to reflect increased admissions and a lower average length of stay.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Globus Medical (GMED), backed by the NuVasive merger and its prominence in the musculoskeletal field.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Globus Medical (GMED) Gains From Innovation Amid Macro Issues
by Zacks Equity Research
Globus Medical (GMED) is particularly seeing notable gains in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) on growing demand for musculoskeletal devices and its strong solvency position.
Globus Medical (GMED) Down 3.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay
by Zacks Equity Research
Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Globus Medical (GMED) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Globus Medical's (GMED) legacy business continues to drive share growth across its U.S. spine and trauma portfolios in the third quarter.
Globus Medical (GMED) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Why Globus Medical (GMED) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.